Table 4.
Univariate analysis
| Infection group (n=19) | Non-infection group (n=97) | t/X2 | P | |
|---|---|---|---|---|
| Age (years) | 36.47±4.27 | 36.15±5.45 | 0.242 | 0.810 |
| Gender | 1.690 | 0.194 | ||
| Male | 14 (73.68) | 56 (57.73) | ||
| Female | 5 (26.32) | 41 (42.27) | ||
| Course of disease (years) | 4.11±0.67 | 3.67±0.55 | 3.074 | 0.003 |
| BMI (kg/m2) | 20.74±2.10 | 21.16±2.37 | 0.719 | 0.474 |
| Type | 2.003 | 0.157 | ||
| Ulcerative colitis | 12 (63.16) | 76 (78.35) | ||
| Crohn’s disease | 7 (36.84) | 21 (21.65) | ||
| Lesion site | 0.790 | 0.674 | ||
| Rectum | 7 (36.84) | 26 (26.80) | ||
| Left colon | 4 (21.05) | 23 (23.71) | ||
| Extensive colon | 8 (42.11) | 48 (49.48) | ||
| History of smoking | 7 (36.84) | 25 (25.77) | 0.975 | 0.324 |
| History of alcoholism | 7 (63.16) | 21 (74.23) | ||
| Place of residence | 0.602 | 0.438 | ||
| Rural area | 14 (73.68) | 79 (81.44) | ||
| Urban area | 5 (26.32) | 18 (18.56) | ||
| IgA at admission | 2.45±0.47 | 2.15±0.57 | 2.222 | 0.028 |
| IgG at admission | 19.62±1.89 | 18.21±1.95 | 2.896 | 0.005 |
| IgM at admission | 2.24±0.42 | 1.97±0.54 | 2.058 | 0.042 |
| TNF-α at admission | 3.53±0.97 | 3.04±0.78 | 2.402 | 0.018 |
| IL-6 at admission | 26.80±5.28 | 23.98±4.42 | 2.461 | 0.015 |
| CRP at admission | 21.91±4.53 | 16.15±4.95 | 4.699 | <0.001 |
| CAI score at admission | 4.95±1.22 | 4.38±0.97 | 2.242 | 0.027 |
| EAI score at admission | 8.53±1.90 | 6.86±2.23 | 3.052 | 0.003 |
| Treatment mode | 1.001 | 0.317 | ||
| Mesalazine alone | 11 (57.89) | 44 (45.36) | ||
| Salazine combined with probiotics | 8 (42.11) | 53 (54.64) |
BMI, Body Mass Index; EAI, Endoscopic Activity Index; CRP, C-reactive Protein; IgA, Immunoglobulin A; IgG, Immunoglobulin G; IgM, Immunoglobulin M; TNF-α, Tumor Necrosis Factor-α; IL-6, Interleukin-6.